1, Guangzhou Lingnan Group Holdings Company Limited(000524) : with the popularization of covid-19 vaccination and the launch of specific drugs, it is expected to promote the recovery and development of tourism market in the future
Guangzhou Lingnan Group Holdings Company Limited(000524) ( Guangzhou Lingnan Group Holdings Company Limited(000524) ) announced the changes. At present, although the Chinese tourism market is affected by the epidemic situation in various places and the outbound tourism market has not been restarted, with the popularization of covid-19 vaccine and the continuous introduction of specific drugs, it is expected to usher in more positive factors to promote the recovery and development of the tourism market in the future. Facing the market changes after the normalization of epidemic prevention and control, the company will actively grasp the new demand, integrate into the new development pattern, constantly deepen the transformation and upgrading, innovate and supply in one main and multiple ways, and continue to promote the layout of the company’s Pan tourism industry ecosystem.
2, Beijing Shougang Co.Ltd(000959) : net profit of 7.024 billion yuan in 2021, with a year-on-year increase of 293%
Beijing Shougang Co.Ltd(000959) ( Beijing Shougang Co.Ltd(000959) ) disclosed the performance express. In 2021, the company’s total operating revenue was 133398 billion yuan, a year-on-year increase of 66.85%; The net profit attributable to the parent company was 7.024 billion yuan, a year-on-year increase of 293.19%.
3, Gotion High-Tech Co.Ltd(002074) : Planning Overseas issuance of global depositary receipts and listing on the Swiss stock exchange
Gotion High-Tech Co.Ltd(002074) ( Gotion High-Tech Co.Ltd(002074) ) announced that the company plans to issue global depositary receipts overseas and list them on the Swiss stock exchange. The company said that at present, it has reached strategic cooperation and signed product sales orders with many international customers such as Volkswagen and Tata group. This GDR issuance and listing will help to expand the global market share of the company’s products.
4, China Meheco Group Co.Ltd(600056) : covid-19 virus treatment drugs may affect the sales price if they are included in the national medical insurance
China Meheco Group Co.Ltd(600056) ( China Meheco Group Co.Ltd(600056) ) issued a notice on the issue of public health. In March 15th, the national health and Health Committee issued the New Coronavirus pneumonia diagnosis and treatment plan (trial version ninth). The Pfizer Inc COVID-19 virus treatment drug PAXLOVID was included in the ninth edition of the diagnosis and treatment plan, but it has not yet entered the national health insurance. If it is included in the national medical insurance, it may have an impact on the sales price. The company signed an agreement with Pfizer Inc in March 9th, and the company will be responsible for the commercial operation of Pfizer Inc COVID-19 virus PAXLOVID in Chinese mainland market during the agreement period (2022). Xiaocai note: as of today’s close, China Meheco Group Co.Ltd(600056) has increased by 153% in the last 15 trading days.
5, Lucky Harvest Co.Ltd(002965) : received the letter of intent for fixed-point project, and the estimated transaction amount is 3-3.5 billion yuan
Lucky Harvest Co.Ltd(002965) ( Lucky Harvest Co.Ltd(002965) ) announced that the company and its wholly-owned subsidiary Changshu Xiangxin received 14 letters of intent for fixed-point projects from customers related to power batteries from January to March, confirming that the company and Changshu Xiangxin are suppliers of many new energy vehicle power battery box products, with an estimated project life cycle of 2-8 years and an estimated project transaction amount of 3-3.5 billion yuan, The end customers of the project include Chinese independent automobile brands and joint venture brands.
6, Yifeng Pharmacy Chain Co.Ltd(603939) : antigen detection kit will be officially put on sale in retail pharmacies in the next 2-3 days
Yifeng Pharmacy Chain Co.Ltd(603939) ( Yifeng Pharmacy Chain Co.Ltd(603939) ) disclosed the announcement on the minutes of investor relations activities. We believe that the sales of antigen detection kits play a positive role in promoting the passenger flow of retail pharmacies, and the continuous growth of passenger flow is one of the most important factors for the growth of the company’s performance. At present, the company is actively allocating the supply of goods, and has reached a business cooperation agreement with the manufacturer. The commodity will also be officially put on the shelves in retail pharmacies in the next 2-3 days. In the follow-up, the company will actively prepare and transfer goods to ensure and meet the needs of residents for self-detection of covid-19 virus.
7, China Molybdenum Co.Ltd(603993) : from January to February, the company’s cobalt production increased by 52% year-on-year
China Molybdenum Co.Ltd(603993) ( China Molybdenum Co.Ltd(603993) ) announced that from January to February 2022, the company seized the favorable opportunity of the market and went all out to stabilize and increase production. The output of the company’s main products copper, cobalt and niobium increased by 20%, 52% and 42% respectively year-on-year. The output of molybdenum and tungsten products decreased year-on-year due to the restriction of environmental protection control in major international events. At the same time, benefiting from the year-on-year increase in the sales prices of all products, the company’s main business indicators were better than expected and achieved a good start of the year.
8, Yongxing Special Materials Technology Co.Ltd(002756) : from January to February, the net profit of lithium new energy business increased by about 3700% year-on-year
Yongxing Special Materials Technology Co.Ltd(002756) ( Yongxing Special Materials Technology Co.Ltd(002756) ) announced that according to the preliminary accounting of the company, from January to February 2022, the company realized an operating revenue of about 1.58 billion yuan, a year-on-year increase of about 96%, and a net profit attributable to the parent company of about 490 million yuan, a year-on-year increase of about 650%. The company’s performance growth is mainly due to the continuous rapid development of lithium battery new energy industry, which drives the rising price of lithium carbonate. From January to February 2022, the company’s lithium new energy business achieved an operating revenue of about 620 million yuan, a year-on-year increase of about 670%, and a net profit attributable to the parent company of about 420 million yuan, a year-on-year increase of about 3700%.
9, Guangdong No.2 Hydropower Engineering Company Ltd(002060) : it is proposed to invest 6.3 billion yuan to build a new energy power generation project with a total installed capacity of 1.05 million KW
Guangdong No.2 Hydropower Engineering Company Ltd(002060) ( Guangdong No.2 Hydropower Engineering Company Ltd(002060) ) announced that Xinjiang Guangdong No.2 Hydropower Engineering Company Ltd(002060) a wholly-owned subsidiary of the company signed a framework agreement with the people’s Government of Weining County, Bijie City, Guizhou Province, and plans to invest in the construction of a new energy power generation project with a total installed capacity of 1.05 million KW in Weining County, with a total investment of about 6.3 billion yuan. Among them, the proposed construction scale of distributed photovoltaic project is about 50000 kW, with a total investment of about 300 million yuan; The centralized photovoltaic power generation project is 800000 kW (photovoltaic + agriculture, aquaculture, hydrogen production, energy storage, etc.), and the wind power generation project is 200000 kW, with a total investment of about 6 billion yuan.
10, Nanjing Vazyme Biotech Co.Ltd(688105) : sign 215 million yuan New Coronavirus antigen test kit
Nanjing Vazyme Biotech Co.Ltd(688105) ( Nanjing Vazyme Biotech Co.Ltd(688105) ) announced that Nanjing Vazyme Biotech Co.Ltd(688105) medical, a wholly-owned subsidiary of the company, recently signed a distribution contract with Shangyao medical. According to the contract, Nanjing Vazyme Biotech Co.Ltd(688105) medical authorized Shangyao medical is an authorized dealer of Nanjing Vazyme Biotech Co.Ltd(688105) medical in Shanghai, its 100% shareholder Shangyao Holding Co., Ltd. and its subsidiaries in the procurement project of medical materials for public health; The drug treatment plan to Nanjing Vazyme Biotech Co.Ltd(688105) medical procurement total 215 million yuan (including tax) New Coronavirus antigen detection kit. The above purchase amount exceeds 50% of the audited operating cost of the company in the latest fiscal year.
